Clinical Trial Update: A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of bevacizumab, lenalidomide, docetaxel, and prednisone (ART-P) for metastatic castration-resistant prostate cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• Lenalidomide (lenalidomide)
• PREDNISONE (Prednisone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-10-11